(Adds details in paragraph 2-4) Aug 17 (Reuters) – EyePoint said on Monday its experimental eye drug failed to meet its main goal in a late-stage trial. The company was testing the drug, Duravyu,
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)